MPI, Alion to develop drug response predictors for ion channel inhibitors in oncology
DRP, which is a highly validated systems-biology-based biomarker platform, has been developed by MPI and it is useful for identifying likely responding patients for targeted enrollment of cancer
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.